NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Biofortuna today announced a £1.3 million investment ($2.0 million), which will go toward the expansion of its custom service and manufacturing business.

Participants in the funding included all of Biofortuna's current investors, such as the Foresight Group, EV Group, Catapult Venture Managers, Merseyside Special Investment Fund, private investors, and management.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.